We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Catalent Biologics, Triphase Enter ADC License Agreement
News

Catalent Biologics, Triphase Enter ADC License Agreement

Catalent Biologics, Triphase Enter ADC License Agreement
News

Catalent Biologics, Triphase Enter ADC License Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Catalent Biologics, Triphase Enter ADC License Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Catalent and Triphase Accelerator Corporation have announced that Triphase will obtain worldwide rights to further develop Catalent's proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent's wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTagTM technology platform. Catalent will receive an upfront payment and has the potential to earn additional development and commercial milestone payments, plus a royalty on product sales. Triphase will also contract with Catalent for development, manufacturing and analytical services to support a fast path to clinic.

CD22-4AP is a novel, site-specific ADC, targeting CD22, a B-cell restricted sialoglycoprotein that is an important modulator of B-cell signaling and survival, which is expressed on 90% of B-cell malignancies. CD22 is a clinically validated ADC target with potential in Non-Hodgkin's Lymphoma (NHL) and Acute Lymphoid Leukemia (ALL). Catalent's ADC, CD22-4AP, is a site-specific modified humanized antibody conjugated to a toxin payload using Catalent's proprietary Hydrazino-Pictet-Spengler (HIPSTM ) chemistry and proprietary 4AP linker.

Pre-clinical data has shown that this optimization of payload placement and linker composition, combined with the stability afforded by HIPS chemistry, leads to better tolerability and expanded therapeutic index. Dr. Mohit Trikha, Chief Scientific Officer, Executive Vice President and Head of R&D at Triphase, commented, "Given our deep experience in investigating potential treatment for blood cancers and oncology clinical drug development, it is a logical progression for us to explore other approaches for other hematologic tumors. We believe in the potential of Catalent`s SMARTag technology and look forward to advancing CD22-4AP to clinical proof of concept studies.

"Triphase has demonstrated expertise and a track record in advancing pre-clinical oncology candidates to clinical proof of concept," added Mike Riley, Catalent Biologics' Vice President & General Manager. "We look forward to leveraging Triphase`s expertise in combination with our proprietary SMARTag technology and supporting infrastructure to bring this potentially transformational treatment to patients."

Advertisement